Skip to main content
Gerald Horn, MD, Ophthalmology, Hinsdale, IL

Gerald David Horn MD Lumify, PRX100 reading drop (inventor)

Refractive Surgery


Co-Medical Director Lasik Plus Chicago

Join to View Full Profile
  • 3021 Butterfield RoadSte 200Hinsdale, IL 60523

  • Phone+1 630-368-3937

  • Fax+1 630-368-3941

Dr. Horn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Gerald Horn is an ophthalmologist in Hinsdale, IL. He received his medical degree from University of Illinois College of Medicine and has been in practice 40 years. He is experienced in refractive surgery and refractive laser eye surgery.

Education & Training

  • Rush University Medical Center
    Rush University Medical CenterResidency, Ophthalmology, 1978 - 1981
  • Rush University Medical Center
    Rush University Medical CenterResidency, Surgery, 1977 - 1978
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1977

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1978 - 2026
  • Ophthalmology
    American Board of Ophthalmology Ophthalmology

Publications & Presentations

PubMed

Press Mentions

  • LENZ Therapeutics Gets Fresh Set of Eyes with $47M Funding to Bring Eyedrop to Market
    LENZ Therapeutics Gets Fresh Set of Eyes with $47M Funding to Bring Eyedrop to MarketJune 17th, 2021
  • How Breinfuel Was Designed to Enhance the Benefits of Caffeine, Explained by Dr. Gerald Horn
    How Breinfuel Was Designed to Enhance the Benefits of Caffeine, Explained by Dr. Gerald HornDecember 9th, 2020
  • Ocuphire Pharma Announces in-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
    Ocuphire Pharma Announces in-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian PharmaceuticalsJanuary 22nd, 2020
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: